Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias.
Stagno
Fabio
F
Department of Biomedical Sciences, Section of Hematology, University of Catania, Italy. fsematol@tiscali.it
Vigneri
Paolo
P
Del Fabro
Vittorio
V
Stella
Stefania
S
Restuccia
Nunzio
N
Giallongo
Cesarina
C
Massimino
Michele
M
Berretta
Salvatore
S
Pennisi
Maria Stella
MS
Tibullo
Daniele
D
Tirrò
Elena
E
Buscarino
Calogero
C
Messina
Angelo
A
Di Raimondo
Francesco
F
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000473:pathology / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy*; D000068818:Cetuximab; D003131:Combined Modality Therapy; D000069439:Dasatinib; D004427:Ear Diseases / Q000473:pathology / Q000628:therapy; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D007636:Keratoacanthoma / Q000473:pathology / Q000628:therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D008297:Male; D016609:Neoplasms, Second Primary / Q000473:pathology / Q000628:therapy*; D011743:Pyrimidines / Q000008:administration & dosage; D011878:Radiotherapy; D012535:Scalp / Q000473:pathology; D013844:Thiazoles / Q000008:administration & dosage; D014062:Tongue Neoplasms / Q000473:pathology; D014827:Vocal Cords / Q000473:pathology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D011743:Pyrimidines; D013844:Thiazoles; D016044:Fusion Proteins, bcr-abl; D000068818:Cetuximab; D000069439:Dasatinib